Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background/Objectives: Pilocytic astrocytomas (PAs) are the most frequent astrocytomas in children and adolescents. Methilthioadenosine phosphorylase (MTAP) is a tumor-suppressor gene, the loss of expression of which is associated with a poor prognosis and better response to specific chemotherapy in leukemia and non-small-cell lung cancer. The expression of MTAP in brain tumors remains largely unknown and its biological role in PA is still unexplored. Our aims were to describe the immunohistochemical MTAP expression in a series of PAs and relate it to the clinicopathological features of the patients. Methods: We assessed MTAP expression on immunohistochemistry in 69 pediatric and adult patients with PA in a tissue microarray platform. Results: Retained expression of MTAP was seen in >85% of the tumors compared to in the nonneoplastic adjacent tissue. Only 3 supratentorial tumors showed a complete loss of MTAP expression. No significant association with clinicopathological features or overall survival of the patients was found. Conclusions: MTAP expression is retained in PAs and is not an outcome predictor for these tumors. Nevertheless, a subset of patients with PAs exhibiting a loss of MTAP could potentially benefit from treatment with specific chemotherapy, especially when lesions are recurrent or surgical resection is not recommended.

Related collections

Author and article information

Journal

Journal ID (publisher-id): PAT

Journal ID (nlm-ta): Pathobiology

Journal ID (doi): 10.1159/issn.1015-2008

Title: Pathobiology

Publisher: S. Karger AG

ISSN (Print): 1015-2008

ISSN (Electronic): 1423-0291

Publication date Subscription-year: 2015

Publication date (Print): July 2015

Publication date (Electronic): 18 June 2015

Volume: 82

Issue: 2

Pages: 84-89

Affiliations

^aMolecular Oncology Research Center, Departments of ^bPathology and ^cNeurosurgery, Barretos Cancer Hospital, Barretos, ^dRibeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil; ^eLife and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, and ^fICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal

Author notes

*Rui Manuel Reis, PhD, Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela 1331, Barretos-SP 14784-400 (Brazil), E-Mail ruireis.hcb@gmail.com

Article

Publisher ID: 430956 Other ID: Pathobiology 2015;82:84-89

DOI: 10.1159/000430956

PubMed ID: 26088413

SO-VID: 2254b931-09f7-41bf-a5ad-6a8eb016999b

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 16 December 2014

Date accepted : 27 April 2015

Page count

Figures: 2, Tables: 2, References: 50, Pages: 6

Comments

Comment on this article

scite_

Cited by 5

See all cited by

- Version 1

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before May 31, 2024